MedTrace Logo

The Effects of Remimazolam on Cerebral Blood Flow Following General Anesthesia Induction

NCT07303985 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-04-15

No results posted yet for this study

Summary

This study will enroll 40 subjects aged 18 years or older scheduled for elective surgery under general anesthesia with endotracheal intubation. Basic medical history information will be collected. Subjects will be divided into two groups of 20 each: a remimazolam group and a propofol group. The study period will span from one day before surgery to one day after surgery. The study will assess middle cerebral artery cerebral blood flow following general anesthesia induction and postoperative anesthesia recovery.

Conditions

  • Cerebral Blood Flow

Interventions

DRUG

Remimazolam

Remimazolam is used as the sedative agent during the anesthesia induction period (administer remimazolam as an intravenous bolus of 0.3 mg/kg for induction).

DRUG

Propofol (Group P)

Propofol is used as the sedative agent during the anesthesia induction period (administer propofol at 2 mg/kg for induction).

Sponsors & Collaborators

  • Jun Zhang

    lead OTHER

Principal Investigators

  • Jun Zhang · Fudan University Shanghai Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-29
Primary Completion
2026-02-28
Completion
2026-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07303985 on ClinicalTrials.gov